Skip to main content

Drug-Drug Interaction (DDI)

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
2
ASP3652Phase 11 trial
rosuvastatinPhase 1Small Molecule1 trial
Active Trials
NCT01797198Completed48Est. Jun 2012
NCT02083627Completed25Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Astellasrosuvastatin
AstellasASP3652

Clinical Trials (2)

Total enrollment: 73 patients across 2 trials

NCT02083627Astellasrosuvastatin

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects

Start: Feb 2013Est. completion: Mar 201325 patients
Phase 1Completed
NCT01797198AstellasASP3652

A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects

Start: Apr 2012Est. completion: Jun 201248 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.